Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba:: implications for stopping polio vaccination after global eradication

被引:33
作者
Lago, PM
Cáceres, VM
Galindo, MA
Gary, HE
Valcarcel, M
Barrios, J
Sarmiento, L
Avalos, I
Bravo, JA
Palomera, R
Bello, M
Sutter, RW
Pallansch, MA
de Quadros, CA
机构
[1] Pedro Kouri Inst Trop Med, Autopista Novia Mediodia, Havana, Cuba
[2] Ctr Dis Control & Prevent, Natl Immunizat Program, Vaccine Prevent Dis Eradicat Div, Atlanta, GA 30333 USA
[3] Minist Publ Hlth Cuba, Havana, Cuba
[4] Prov Ctr Hyg & Epidemiol, Havana, Cuba
[5] Pan Amer Hlth Org, Washington, DC USA
关键词
poliomyelitis; polioviruses; eradication; vaccine; excretion; virus; oral polio vaccine; vaccine Sabin; immunization; circulation; transmission; Cuba;
D O I
10.1093/ije/30.5.1029
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background With substantial progress made toward polio eradication, developing the appropriate strategy for discontinuing global oral poliovirus vaccine (OPV) after global eradication becomes increasingly important. At issue is the theoretical risk of independent circulation of potentially virulent OPV-derived strains. Because Cuba uses OPV only in mass campaigns, it represents an ideal site to assess vaccine-derived poliovirus persistence. Methods Infants born after the 1997 biannual mass campaigns were evaluated for past (neutralizing antibody) or current (virus excretion) evidence of vaccine-derived poliovirus exposure. We obtained sera and/or stool specimens from 861 infants; a second serum from 218 infants. Results All stool specimens were poliovirus negative. Of 762 infants, 113 (14.8%) had initially detectable poliovirus type I antibody, 193 (25.3%) type 2, and 94 (12.3%) type 3. A precipitous antibody decline occurred in initially positive sera. Conclusions Our results suggest that in a country with high population immunity, vaccine-derived virus is unlikely to establish ongoing circulation.
引用
收藏
页码:1029 / 1034
页数:6
相关论文
共 17 条
[1]  
*CDC, 2001, MMWR-MORBID MORTAL W, V50, P320
[2]  
*CDCP, 1999, STOPP POL VACC ISS W
[3]  
*CDCP, 2000, MMWR-MORBID MORTAL W, V49, P656
[4]  
*CDCP, 2000, MMWR-MORBID MORTAL W, V49, P568
[5]  
DASILVA E, 1998, M SCI BAS STOPP POL
[6]   VIRUS EXCRETION AFTER MASS VACCINATION WITH ATTENUATED POLIOVIRUSES IN HUNGARY [J].
DOEMOEK, I ;
JANCSO, A ;
MOLNAR, E .
BRITISH MEDICAL JOURNAL, 1961, 1 (523) :1410-&
[7]   A theoretical framework for evaluating the sensitivity of surveillance for detecting wild poliovirus .1. Factors affecting detection sensitivity in a person with acute flaccid paralysis [J].
Gary, HE ;
Sanders, R ;
Pallansch, MA .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 :S135-S140
[8]  
GONZALEZ OE, 1987, J HYG EPID MICROB IM, V31, P381
[9]   Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient [J].
Kew, OM ;
Sutter, RW ;
Nottay, BK ;
McDonough, MJ ;
Prevots, DR ;
Quick, L ;
Pallansch, MA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2893-2899
[10]   Ending polio immunization: when and how are we sure that the needle is out of the haystack? [J].
Kimman, TG ;
Koopmans, MPG ;
van der Avoort, HGAM .
VACCINE, 1999, 17 (7-8) :624-627